Análisis de la pertinencia de escalas de evaluación cognitiva y de funcionamiento ocupacional para el tamizaje y diagnóstico de alteraciones neurocognitivas asociadas al VIH. revisión sistemática de la literatura

dc.contributorMolina Castaño, Carlos Federico
dc.contributorTrillos, Carlos Enrique
dc.creatorEstrada Bonilla, Maryi Viviana
dc.creatorAguia, Karen
dc.date.accessioned2019-10-29T12:06:17Z
dc.date.accessioned2022-09-22T15:01:35Z
dc.date.available2019-10-29T12:06:17Z
dc.date.available2022-09-22T15:01:35Z
dc.date.created2019-10-29T12:06:17Z
dc.identifierhttps://repository.urosario.edu.co/handle/10336/20501
dc.identifierhttps://doi.org/10.48713/10336_20501
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3444334
dc.description.abstractHIV-Associated Neurocognitive Disorder (HAND) is recognized as a current issue in people living with HIV (PLWH). Assessment processes for screening and diagnosis of HAND are heterogeneous y lack of consensus. This has triggered differences in prevalence report across the word and difficulties in the identification of comparable data. A systematic review was conducted to determine pertinence of cognitive assessment and occupational functioning scales for HAND screening and diagnosis analyzing cognitive domains, screening, occupational participation and mental health. There were 114 cross-sectional, case and control, cohort, and clinical trials studies included in the systematic review. Trail Making Test (TMT) and Stroop Color Word Test (SCWT) scales were identified as the most pertinent para cognitive domains assessment. As for occupational participation, instruments focusing on evaluation occupational performance during the execution of activities are needed, for complementing self-report scales such as The Patients Assessment of Own Functioning Inventory (PAOFI). Mental health is determined as a variable to evaluate transversally, due to the fact that is considered a confounding in the diagnosis of HAND.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherMaestría en Epidemiología
dc.publisherMaestría en Actividad Física y Salud
dc.rightshttp://creativecommons.org/licenses/by-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsAtribución-SinDerivadas 2.5 Colombia
dc.sourceCenters for Disease Control and Prevention (CDC). HIV/AIDS [Internet]. 2019 [citado 21 de julio de 2019]. Disponible en: https://www.cdc.gov/hiv/basics/whatishiv.html
dc.sourceUNAIDS. AIDSinfo [Internet]. [citado 21 de julio de 2019]. Disponible en: https://aidsinfo.unaids.org/
dc.sourceRobertson K, Liner J, Heaton R. Neuropsychological Assessment of HIV-Infected Populations in International Settings. Neuropsychol Rev. 1 de junio de 2009;19(2):232-49.
dc.sourceOpacich K. Human Immunodefciency Virus. En: Trombly Latham C, Vining Radomski M, editores. Occupational therapy for physical dysfunction. Seventh edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014. p. 1353-7.
dc.sourceGustafson DR, Mielke MM, Tien PC, Valcour V, Cohen M, Anastos K, et al. Anthropometric measures and cognition in middle-aged HIV-infected and uninfected women. The Women’s Interagency HIV Study. J Neurovirol. diciembre de 2013;19(6):574-85.
dc.sourceLawler K, Jeremiah K, Mosepele M, Ratcliffe SJ, Cherry C, Seloilwe E, et al. Neurobehavioral Effects in HIV-Positive Individuals Receiving Highly Active Antiretroviral Therapy (HAART) in Gaborone, Botswana. Myer L, editor. PLoS ONE. 18 de febrero de 2011;6(2):e17233.
dc.sourceBonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy F-A, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS. enero de 2013;27(3):391-400.
dc.sourceTierney SM, Sheppard DP, Kordovski VM, Faytell MP, Avci G, Woods SP. A comparison of the sensitivity, stability, and reliability of three diagnostic schemes for HIV-associated neurocognitive disorders. J Neurovirol. junio de 2017;23(3):404-21.
dc.sourcePalacio M, Álvarez S, Muñoz-Fernández MÁ. HIV-1 infection and neurocognitive impairment in the current era: NeuroAIDS in the current era. Rev Med Virol. enero de 2012;22(1):33-45.
dc.sourceGrant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 10 de junio de 2014;82(23):2055-62.
dc.sourceLivelli A, Orofino GC, Calcagno A, Farenga M, Penoncelli D, Guastavigna M, et al. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. Front Behav Neurosci [Internet]. 16 de noviembre de 2015 [citado 21 de julio de 2019];9. Disponible en: http://journal.frontiersin.org/Article/10.3389/fnbeh.2015.00306/abstract
dc.sourceGuía Clínica EACS 2017 [Internet]. 2017 oct p. 73. Disponible en: http://www.eacsociety.org/files/guidlines-9.0-spanish.pdf
dc.sourceRobbins RN, Joska JA, Thomas KGF, Stein DJ, Linda T, Mellins CA, et al. Exploring the Utility of the Montreal Cognitive Assessment to Detect HIV-Associated Neurocognitive Disorder: The Challenge and Need for Culturally Valid Screening Tests in South Africa. Clin Neuropsychol. abril de 2013;27(3):437-54.
dc.sourceHill-Jarrett TG, Ikanga J, Stringer AY. Neuropsychology in Africa. Neuropsychol Afr Encycl Clin Neuropsychol. 2018;2444.
dc.sourceLopardo GD, Bissio E, Iannella M del C, Crespo AD, Garone DB, Cassetti LI. Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection. J Acquir Immune Defic Syndr 1999. 1 de diciembre de 2009;52(4):488-92.
dc.sourceHinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS Lond Engl. 1 de enero de 2004;18 Suppl 1:S19-25.
dc.sourceThe Mind Exchange Working Group, Antinori A, Arendt G, Grant I, Letendre S, Chair, et al. Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clin Infect Dis. 1 de abril de 2013;56(7):1004-17.
dc.sourceCarvalhal A, Gill MJ, Letendre SL, Rachlis A, Bekele T, Raboud J, et al. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. J Neurovirol. junio de 2016;22(3):349-57
dc.sourceKamminga J, Cysique LA, Lu G, Batchelor J, Brew BJ. Validity of cognitive screens for HIV-associated neurocognitive disorder: a systematic review and an informed screen selection guide. Curr HIV/AIDS Rep. diciembre de 2013;10(4):342-55.
dc.sourceAnderson AM, Lennox JL, Nguyen ML, Waldrop-Valverde D, Tyor WR, Loring DW. Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment. J Neurovirol. 2016;22(6):816-22.
dc.sourceThe Mind Exchange Working Group, Antinori A, Arendt G, Grant I, Letendre S, Chair, et al. Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program. Clin Infect Dis. 1 de abril de 2013;56(7):1004-17.
dc.sourceJoint United Nations Programme on HIV/AIDS (UNAIDS). Global Report: UNAIDS report on the global AIDS epidemic 2013. 2013. 31. Joint United Nations Programme on HIV/AIDS (UN)
dc.sourceBennett JE, Dolin R, Blaser MJ, editores. Neurological Diseases Caused by Human Immunodeficiency Virus. En: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Eighth edition. Philadelphia, PA: Elsevier/Saunders; 2015. p. 1482-588.
dc.sourceSu T, Schouten J, Geurtsen GJ, Wit FW, Stolte IG, Prins M, et al. Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection: AIDS. enero de 2015;1.
dc.sourceKallail KJ, Downs D, Scherz J, Sweet D, Zackula RE. Prevalence of Communication Disorders in HIV-Infected Adults. J Int Assoc Provid AIDS Care JIAPAC. enero de 2014;13(1):8-11.
dc.sourceMaj M, Satz P, Janssen R, Zaudig M, Starace F, D’Elia L, et al. WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry. enero de 1994;51(1):51-61.
dc.sourcethe AIDS Clinical Trials Group, Robertson K, Kumwenda J, Supparatpinyo K, Jiang JH, Evans S, et al. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol. octubre de 2011;17(5):438-47.
dc.sourceSacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 26 de enero de 2016;86(4):334-40.
dc.sourceTroncoso FT, Conterno L de O. Prevalence of neurocognitive disorders and depression in a Brazilian HIV population. Rev Soc Bras Med Trop. agosto de 2015;48(4):390-8.
dc.sourceWojna V, Skolasky RL, Hechavarría R, Mayo R, Selnes O, McArthur JC, et al. Prevalence of human immunodeficiency virus–associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol. enero de 2006;12(5):356-64.
dc.sourceMorales D, Acevedo SF, Skolasky RL, Hechavarria R, Santiago S, De La Torre T, et al. Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women. J Neurovirol. diciembre de 2012;18(6):488-502.
dc.sourceLadrón de Guevara H. A, Salas R. M, González B. E, Araya Cortéz L. Diagnóstico neurológico y psicológico en la evaluación del paciente VIH. Bol Hosp S Juan Dios. agosto de 1998;45(4):222-8.
dc.sourceFondo Colombiano de Enfermedades de Alto Costo (CAC). Situación del VIH Sida en Colombia [Internet]. Bogotá, Colombia; Report No.: ISSN: 2344-7702. Disponible en: http://cuentadealtocosto.org/images/Publicaciones/2018/Situacion_VIH_2017..pdf
dc.sourceMinisterio de Salud de Colombia. Boletín de Salud Mental - Demencia [Internet]. Subdirección de enfermedades no transmisibles; Report No.: Boletín de Salud Mental No. 3, octubre de 2017. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ENT/Boletin-demencia-salud-mental.pdf
dc.sourceMinisterio de Salud y Protección Social, Fondo de Población de las Naciones Unidas - UNFPA. Guía de Práctica Clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH/Sida en adolescentes (con 13 años o más de edad) y adultos. [Internet]. Bogotá, Colombia; 2014. Disponible en: http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Otros_conv/GPC_VIH_adolescentes/GPC_vih_adolescentes_profesionales.aspx
dc.sourcePino-Melgarejo M, Omar-Martínez E. Cognición y VIH. Algunas consideraciones. Santiago. septiembre de 2014;(135):664-74.
dc.sourceBennett JE, Dolin R, Blaser MJ, editores. General manifestations of Human Immunodeficiency virus infection. En: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Eighth edition. Philadelphia, PA: Elsevier/Saunders; 2015. p. 1547.
dc.sourceMcArthur JC, Steiner J, Sacktor N, Nath A. HIV-associated neurocognitive disorders: ‘mind the gap’. Ann Neurol. 2010;NA-NA.
dc.sourceVan Gorp W, Root J. CNS infection: HIV associated neurocognitive compromise. En: Textbook of Clinical Neuropsychology. Great Britain: Taylor & Francis; p. 508-20.
dc.sourceGrant I, Sacktor N. HIV-Associated Neurocognitive Disorders. En: Gendelman HE, editor. The neurology of AIDS. New York: Oxford University Press; 2012. p. 408.
dc.sourceTozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. Aids. 1999;13(14):1889–1897.
dc.sourceAntinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
dc.sourceValcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for Cognitive Impairment in Human Immunodeficiency Virus. Clin Infect Dis. 15 de octubre de 2011;53(8):836-42.
dc.sourceGandhi NS, Moxley RT, Creighton J, Roosa HV, Skolasky RL, Selnes OA, et al. Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Ther. mayo de 2010;4(3):371-9.
dc.sourceMcArthur JC, Steiner J, Sacktor N, Nath A. HIV-associated neurocognitive disorders: ‘mind the gap’. Ann Neurol. 2010;NA-NA.
dc.sourceGandhi NS, Moxley RT, Creighton J, Roosa HV, Skolasky RL, Selnes OA, et al. Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Ther. mayo de 2010;4(3):371-9.
dc.sourceGisslén M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis [Internet]. diciembre de 2011 [citado 21 de julio de 2019];11(1). Disponible en: https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-11-356
dc.sourceMcArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders mind the gap. Ann Neurol. 2010;67(6):699-714.
dc.sourceNeuropsychological Assessment of HIV-Infected Populations in International Settings | SpringerLink [Internet]. [citado 13 de julio de 2019]. Disponible en: https://link-springer-com.ez.urosario.edu.co/article/10.1007%2Fs11065-009-9096-z
dc.sourceThe Translational Methamphetamine AIDS Research Center (TMARC) Group, Doyle KL, Morgan EE, Morris S, Smith DM, Little S, et al. Real-world impact of neurocognitive deficits in acute and early HIV infection. J Neurovirol. diciembre de 2013;19(6):565-73.
dc.sourceHeaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc [Internet]. mayo de 2004 [citado 21 de julio de 2019];10(03). Disponible en: http://www.journals.cambridge.org/abstract_S1355617704102130
dc.sourceThomas H. Step 1: Determine what is being analyzed. En: Occupation-based activity analysis. Second edition. Thorofare, NJ: SLACK Incorporated; 2015. p. 19.
dc.sourceGillen G, Boyt Schell BA. Introducción a la evaluación, la intervención y los resultados de las ocupaciones. En: Terapia ocupacional. 12a ed. Buenos Aires: Editorial Médica Panamericana; 2016. p. 607.
dc.sourceValcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for Cognitive Impairment in Human Immunodeficiency Virus. Clin Infect Dis. 15 de octubre de 2011;53(8):836-42.
dc.sourceEmlet CA. A Comparison of HIV Stigma and Disclosure Patterns Between Older and Younger Adults Living with HIV/AIDS. AIDS Patient Care STDs. mayo de 2006;20(5):350-8.
dc.sourceEmlet CA, Farkas KJ. A Descriptive Analysis of Older Adults with HIV/AIDS in California. Health Soc Work. noviembre de 2001;26(4):226.
dc.sourceShippy RA, Karpiak SE. The aging HIV/AIDS population: Fragile social networks. Aging Ment Health. mayo de 2005;9(3):246-54.
dc.sourceWoods SP, Moore DJ, Weber E, Grant I. Cognitive Neuropsychology of HIV-Associated Neurocognitive Disorders. Neuropsychol Rev. junio de 2009;19(2):152-68.
dc.sourceRanka JL, Chapparo CJ. Assessment of productivity performance in men with HIV Associated Neurocognitive Disorder (HAND). Work. 2010;(2):193–206.
dc.sourceRanka J. Cognitive Strategy Application during Everyday Task Performance in Men with HIV-1 Dementia. :282.
dc.sourceSacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology. 26 de enero de 2016;86(4):334-40
dc.sourceGallego L, Barreiro P, López-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev. septiembre de 2011;13(3):171-9.
dc.sourceHaddow LJ, Floyd S, Copas A, Gilson RJC. A Systematic Review of the Screening Accuracy of the HIV Dementia Scale and International HIV Dementia Scale. Jiang S, editor. PLoS ONE. 16 de abril de 2013;8(4):e61826.
dc.sourceAntinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
dc.sourceDevelopment of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS) | BMJ Open [Internet]. [citado 22 de julio de 2019]. Disponible en: https://bmjopen.bmj.com/content/6/12/e011458
dc.sourceWells G, Shea B, O’Connell D, Peterson J, Welch M, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. [citado 22 de julio de 2019]. Disponible en: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
dc.sourceHartmann KE, Jerome RN, Lindegren ML, Potter SA, Shields TC, Surawicz TS, et al. Cochrane Risk of Bias Tool [Internet]. Agency for Healthcare Research and Quality (US); 2013 [citado 28 de julio de 2019]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK132494/
dc.sourceSu T, Schouten J, Geurtsen GJ, Wit FW, Stolte IG, Prins M, et al. Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection: AIDS. enero de 2015;1.
dc.sourceTierney SM, Sheppard DP, Kordovski VM, Faytell MP, Avci G, Woods SP. A comparison of the sensitivity, stability, and reliability of three diagnostic schemes for HIV-associated neurocognitive disorders. J Neurovirol. junio de 2017;23(3):404-21.
dc.sourceKinuthia RN, Gakinya BN, Thigiti JM. Relationship between HIV stage and psychomotor speed neurocognitive score at a Kenyan sub-county hospital. Afr J Prim Health Care Fam Med. 31 de agosto de 2016;8(1):e1-8.
dc.sourceZhang Y, Qiao L, Ding W, Wei F, Zhao Q, Wang X, et al. An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China. J Neurovirol. abril de 2012;18(2):120-6.
dc.sourceHeaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. febrero de 2011;17(1):3-16.
dc.sourceSalawu FK, Bwala SA, Wakil MA, Bani B, Bukbuk DN, Kida I. Cognitive function in HIV-seropositive Nigerians without AIDS. J Neurol Sci. 15 de abril de 2008;267(1):142-6.
dc.sourceBlackstone K, Moore DJ, Heaton RK, Franklin DR, Woods SP, Clifford DB, et al. Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc JINS. enero de 2012;18(1):79-88.
dc.sourceSacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. abril de 2002;8(2):136-42.
dc.sourceYakasai AM, Gudaji MI, Muhammad H, Ibrahim A, Owolabi LF, Ibrahim DA, et al. Prevalence and Correlates of HIV-Associated Neurocognitive Disorders (HAND) in Northwestern Nigeria. Neurol Res Int. 2015;2015:486960.
dc.sourceMarquine MJ, Sakamoto M, Dufour C, Rooney A, Fazeli P, Umlauf A, et al. The impact of ethnicity/race on the association between the Veterans Aging Cohort Study (VACS) Index and neurocognitive function among HIV-infected persons. J Neurovirol. 2016;22(4):442-54.
dc.sourceFaílde-Garrido JM, Alvarez MR, Simón-López MA. Neuropsychological impairment and gender differences in HIV-1 infection. Psychiatry Clin Neurosci. octubre de 2008;62(5):494-502.
dc.sourceDufour CA, Marquine MJ, Fazeli PL, Henry BL, Ellis RJ, Grant I, et al. Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. J Neurovirol. octubre de 2013;19(5):410-7.
dc.sourceSalthouse TA. What cognitive abilities are involved in trail-making performance? Intelligence. julio de 2011;39(4):222-32.
dc.sourceScarpina F, Tagini S. The Stroop Color and Word Test. Front Psychol [Internet]. 12 de abril de 2017 [citado 14 de octubre de 2019];8. Disponible en: http://journal.frontiersin.org/article/10.3389/fpsyg.2017.00557/full
dc.sourceRyan JJ, Lopez SJ. Wechsler Adult Intelligence Scale-III. En: Dorfman WI, Hersen M, editores. Understanding Psychological Assessment [Internet]. Boston, MA: Springer US; 2001 [citado 14 de octubre de 2019]. p. 19-42. Disponible en: http://link.springer.com/10.1007/978-1-4615-1185-4_2
dc.sourceKreutzer JS, DeLuca J, Caplan B, editores. Encyclopedia of Clinical Neuropsychology [Internet]. New York, NY: Springer New York; 2011 [citado 14 de octubre de 2019]. Disponible en: http://link.springer.com/10.1007/978-0-387-79948-3
dc.sourceBenedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. Clin Neuropsychol. febrero de 1998;12(1):43-55.
dc.sourceJoska JA, Westgarth-Taylor J, Hoare J, Thomas KG, Paul R, Myer L, et al. Neuropsychological outcomes in adults commencing highly active anti-retroviral treatment in South Africa: a prospective study. BMC Infect Dis. diciembre de 2012;12(1):39.
dc.sourceBottiggi KA, Chang JJ, Schmitt FA, Avison MJ, Mootoor Y, Nath A, et al. The HIV Dementia Scale: Predictive power in mild dementia and HAART. J Neurol Sci. septiembre de 2007;260(1-2):11-5.
dc.sourceSkinner S, Adewale A, DeBlock L, Gill M, Power C. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. abril de 2009;10(4):246-52.
dc.sourceSacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. Aids. 2005;19(13):1367–1374.
dc.sourceTsegaw M, Andargie G, Alem G, Tareke M. Screening HIV-associated neurocognitive disorders (HAND) among HIV positive patients attending antiretroviral therapy in South Wollo, Ethiopia. J Psychiatr Res. 1 de febrero de 2017;85:37-41.
dc.sourceZhao T, Wei B, Long J, Tang X, Zhou M, Dang C. Cognitive disorders in HIV-infected and AIDS patients in Guangxi, China. J Neurovirol. 1 de febrero de 2015;21(1):32-42.
dc.sourceJoska JA, Witten J, Thomas KG, Robertson C, Casson-Crook M, Roosa H, et al. A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa. AIDS Behav. agosto de 2016;20(8):1621-31.
dc.sourceMorgan EE, Woods SP, Scott JC, Childers M, Marquie Beck J, Ellis RJ, et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol. 4 de enero de 2008;30(1):83-90.
dc.sourceFeatured Batteries - Cogstate Ltd [Internet]. Cogstate. [citado 14 de octubre de 2019]. Disponible en: https://www.cogstate.com/clinical-trials/computerized-cognitive-assessment/featured-batteries/
dc.sourceCysique L, Maruff P, Darby D, Brew B. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. febrero de 2006;21(2):185-94.
dc.sourceOverton ET, Kauwe JSK, Paul R, Tashima K, Tate DF, Patel P, et al. Performances on the CogState and Standard Neuropsychological Batteries Among HIV Patients Without Dementia. AIDS Behav. noviembre de 2011;15(8):1902-9.
dc.sourceMoore DJ, Roediger MJP, Eberly LE, Blackstone K, Hale B, Weintrob A, et al. Identification of an abbreviated test battery for detection of HIV-associated neurocognitive impairment in an early-managed HIV-infected cohort. PloS One. 2012;7(11):e47310.
dc.sourceU.S. Department of Health and Human Services, Health Resources and Services Administration, HIV/AIDS Bureau. Guide for HIV/AIDS Clinical Care. abril de 2014;
dc.sourceBloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, et al. A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review. Clin Infect Dis Off Publ Infect Dis Soc Am. 1 de septiembre de 2016;63(5):687-93.
dc.sourceKoski L, Brouillette M-J, Lalonde R, Hello B, Wong E, Tsuchida A, et al. Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment(*). HIV Med. septiembre de 2011;12(8):472-80.
dc.sourceRichardson-Vejlgaard R, Dawes S, Heaton RK, Bell MD. Validity of cognitive complaints in substance-abusing patients and non-clinical controls: the Patient’s Assessment of Own Functioning Inventory (PAOFI). Psychiatry Res. 30 de agosto de 2009;169(1):70-4.
dc.sourcePatton DE, Woods SP, Franklin D, Cattie JE, Heaton RK, Collier AC, et al. Relationship of Medication Management Test-Revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIV. AIDS Behav. noviembre de 2012;16(8):2286-96.
dc.sourceDoyle KL, Woods SP, Morgan EE, Iudicello JE, Cameron MV, Gilbert PE, et al. Health-Related Decision-Making in HIV Disease. J Clin Psychol Med Settings. 2016;23(2):135-46.
dc.sourceThames AD, Arentoft A, Rivera-Mindt M, Hinkin CH. Functional disability in medication management and driving among individuals with HIV: A 1-year follow-up study. J Clin Exp Neuropsychol. enero de 2013;35(1):49-58.
dc.sourceCattie JE, Doyle K, Weber E, Grant I, Woods SP, HIV Neurobehavioral Research Program (HNRP) Group. Planning deficits in HIV-associated neurocognitive disorders: component processes, cognitive correlates, and implications for everyday functioning. J Clin Exp Neuropsychol. 2012;34(9):906-18.
dc.sourceEne L, Franklin DR, Burlacu R, Luca AE, Blaglosov AG, Ellis RJ, et al. Neurocognitive functioning in a Romanian cohort of young adults with parenterally-acquired HIV-infection during childhood. J Neurovirol. octubre de 2014;20(5):496-504.
dc.sourceArentoft A, Byrd D, Monzones J, Coulehan K, Fuentes A, Rosario A, et al. Socioeconomic Status and Neuropsychological Functioning: Associations in an Ethnically Diverse HIV+ Cohort. Clin Neuropsychol. 2015;29(2):232-54.
dc.sourceHeaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 7 de diciembre de 2010;75(23):2087-96.
dc.sourceBeltrán M del C, Freyre M-Á, Hernández-Guzmán L. El Inventario de Depresión de Beck: Su validez en población adolescente. Ter Psicológica. abril de 2012;30(1):5-13.
dc.sourceAmerican Psychological Association (APA). Beck Depression Inventory (BDI) [Internet]. https://www.apa.org. [citado 15 de octubre de 2019]. Disponible en: https://www.apa.org/pi/about/publications/caregivers/practice-settings/assessment/tools/beck-depression
dc.sourceWittchen H-U, Nelson CB. The Composite International Diagnostic Interview: An Instrument for Measuring Mental Health Outcome? En: Thornicroft G, Tansella M, editores. Mental Health Outcome Measures [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 1996 [citado 15 de octubre de 2019]. p. 179-87. Disponible en: https://doi.org/10.1007/978-3-642-80202-7_13
dc.sourceCross S, Önen N, Gase A, Overton ET, Ances BM. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. diciembre de 2013;8(5):1114-22
dc.sourceLawler K, Mosepele M, Ratcliffe S, Seloilwe E, Steele K, Nthobatsang R, et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc. 20 de abril de 2010;13:15.
dc.sourceDawes S, Suarez P, Casey CY, Cherner M, Marcotte TD, Letendre S, et al. Variable patterns of neuropsychological performance in HIV-1 infection. J Clin Exp Neuropsychol. agosto de 2008;30(6):613-26.
dc.sourceWright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, Kongsaengdao S, et al. Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region. Neurology. 1 de julio de 2008;71(1):50-6.
dc.sourcePereda M, Ayuso-Mateos JL, Gómez Del Barrio A, Echevarria S, Farinas MC, García Palomo D, et al. Factors associated with neuropsychological performance in HIV-seropositive subjects without AIDS. Psychol Med. enero de 2000;30(1):205-17.
dc.sourceHeaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, et al. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. HNRC Group. HIV Neurobehavioral Research Center. Psychosom Med. febrero de 1994;56(1):8-17.
dc.sourceGibbs A, Andrewes DG, Szmukler G, Mulhall B, Bowden SC. Early HIV-related neuropsychological impairment: relationship to stage of viral infection. J Clin Exp Neuropsychol. octubre de 1990;12(5):766-80.
dc.sourceYusuf AJ, Hassan A, Mamman AI, Muktar HM, Suleiman AM, Baiyewu O. Prevalence of HIV-Associated Neurocognitive Disorder (HAND) among Patients Attending a Tertiary Health Facility in Northern Nigeria. J Int Assoc Provid AIDS Care. febrero de 2017;16(1):48-55.
dc.sourceFujiwara E, Tomlinson SE, Purdon SE, Gill MJ, Power C. Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). J Clin Exp Neuropsychol. 2015;37(7):733-50.
dc.sourceCrum-Cianflone NF, Moore DJ, Letendre S, Roediger MP, Eberly L, Weintrob A, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013;80(4):371–379.
dc.sourceVance DE, Burrage JW. Sleep disturbances and psychomotor decline in HIV. Percept Mot Skills. junio de 2005;100(3 Pt 2):1004-10.
dc.sourceHinkin CH, Castellon SA, Hardy DJ. Dual task performance in HIV-1 infection. J Clin Exp Neuropsychol. febrero de 2000;22(1):16-24.
dc.sourceWoods SP, Carey CL, Moran LM, Dawson MS, Letendre SL, Grant I. Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. Arch Clin Neuropsychol. 1 de febrero de 2007;22(2):187-95.
dc.sourceChernoff RA, Martin DJ, Schrock DA, Huy MP. Neuropsychological functioning as a predictor of employment activity in a longitudinal study of HIV-infected adults contemplating workforce reentry. J Int Neuropsychol Soc JINS. enero de 2010;16(1):38-48.
dc.sourceYechoor N, Towe SL, Robertson KR, Westreich D, Nakasujja N, Meade CS. Utility of a brief computerized battery to assess HIV-associated neurocognitive impairment in a resource-limited setting. J Neurovirol. 2016;22(6):808-15.
dc.sourceGuías Clínicas EACS Versión 8.0. octubre de 2015;73.
dc.sourceFish J. Lawton-Brody Instrumental Activities of Daily Living Scale. En: Kreutzer JS, DeLuca J, Caplan B, editores. Encyclopedia of Clinical Neuropsychology [Internet]. New York, NY: Springer; 2011 [citado 27 de octubre de 2019]. p. 1438-9. Disponible en: https://doi.org/10.1007/978-0-387-79948-3_1842
dc.sourceRobertson K, Bayon C, Molina J-M, McNamara P, Resch C, Muñoz-Moreno JA, et al. Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care. 2014;26(12):1555-61.
dc.sourceFazeli PL, Marceaux JC, Vance DE, Slater L, Long CA. Predictors of cognition in adults with HIV: implications for nursing practice and research. J Neurosci Nurs J Am Assoc Neurosci Nurses. febrero de 2011;43(1):36-50.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectDesorden Neurocognitivo Asociado a VIH
dc.subjectVirus de Inmunodeficiencia Humana
dc.subjectEvaluación
dc.subjectDiagnóstico
dc.subjectParticipación ocupacional
dc.subjectSalud Mental
dc.subjectRevisión sistemática de la literatura
dc.titleAnálisis de la pertinencia de escalas de evaluación cognitiva y de funcionamiento ocupacional para el tamizaje y diagnóstico de alteraciones neurocognitivas asociadas al VIH. revisión sistemática de la literatura
dc.typemasterThesis


Este ítem pertenece a la siguiente institución